Investors

Corporate Profile

Clene is a clinical-stage biopharmaceutical company dedicated to revolutionizing the treatment of neurodegenerative diseases to restore and protect neuronal health and function. Our nanotherapeutics target cellular energy impairments that are common to many diseases.

News Releases

August 30, 2023
Clene to Present at Upcoming September Conferences
SALT LAKE CITY, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to...
August 29, 2023
Clene Reports Significantly Improved Survival Benefit of 19.3 Months and Significantly Delayed Clinical Worsening in Rescue-Als Open-Label Extension Two Year Follow-Up
19.3 month significant survival difference for CNM-Au8 ® treated participants versus placebo 52% significant decreased risk of ALS clinical worsening events Over 475 years of CNM-Au 8 treatment exposure without any identified safety signals SALT LAKE CITY, Aug....
August 14, 2023
Clene Reports Second Quarter 2023 Financial Results and Operating Highlights
Reported statistically significant reductions in plasma neurofilament light chain (NfL) levels compared to placebo at 24 weeks (p=0.04) in patients treated with CNM-Au8 ® in the HEALEY ALS Platform trial Announced publication of the results of the Phase 2 RESCUE ALS study and its open-label...

Investor Presentation

Revolutionizing the treatment of neurodegenerative diseases to restore and protect neuronal health and function.

Download PDF